Flow cytometry makers |
Source |
Target |
Conclusion |
Reference |
CD133 (+), VEGFR-2(+) |
peripheral blood |
Correlation between EPC and
PAH |
The number of EPC decreased in PAH patients |
(H. X. Sun et al.,
2019) |
CD34(+), CD146(+), CD45(+), CD309(+) |
Bone marrow |
Gene editing EPC
therapy |
BMPR2-expressing EPC alleviate PAH |
(Harper et al.,
2019) |
CD34(+), CD133(+), CD309(+) |
peripheral blood |
Drug effect to EPC and
PAH |
Riociguat increase the number of EPC to protect CTEPH |
(Yamamoto
et al., 2020) |
CD34(+) CD31(+), CD144(+), VEGFR-2(+), eNOS (+) |
peripheral blood |
Regulatory Pathway of EPC |
Stimulation of NOX2, NOX4 and VPO1 induce
EPC’s apoptosis and dysfunction |
(E. L. Wang et al.,
2019) |
sca-1(+), CD117(+),
VEGFR-2(+)
|
Bone marrow
|
extracellular vesicles’ different effect under different
microenvironment
|
MSC-EV reduce the number of EPC in increase the expression of EPC genes
in MCT-PH mice
|
(J. M. Aliotta et al., 2017)
|
CD31(+), VEGFR-2(+), CD144(+), CD34(+), CD14(+) |
peripheral blood |
Factors influence to distribution of EPC |
chemokine and cell Adhesion
Molecules attract EPC to lung |
(Y. Liu et al., 2020) |
CD34(+), CD133(+), CD31(+), CD45(+) |
Bone marrow |
Drug effect to EPC
and PAH |
pinocembrin has a supportive effect to EPC in MCT-PH rats |
(Ahmed, Rizk, & El-Maraghy, 2017) |
CD45(+), CD34(+), CD133(+) |
Bone marrow |
Correlation between EPC and
PAH |
COPD patients have a lower level of EPCs |
(Pizarro et al.,
2014) |
CD34(+), VEGFR-2(+) |
Peripheral blood and lung tissue |
Correlation
between EPC and PAH |
COPD patients have a lower level of EPCs, but
COPD-PH patients have a higher level of EPCs |
(Y. Yang et al.,
2018) |
ZsGreen (+), CD117(+), CD45(+) |
Bone marrow |
Correlation between EPC
and EHT |
Sugen-hypoxia mice’s EPCs unable to transfer PH pathology to
recipient mice |
(Liang et al., 2017) |
CD34(+), CD45(+), CD14(+) |
Peripheral blood |
Function of EPCs |
different markers EPCs have different function |
(Foris et al.,
2016) |
CD133 (+), VEGFR-2(+) |
Peripheral blood |
Correlation between EPC and
PAH |
EPC number and vasculogenesis increase in 48h, but significantly
reduce after 6 weeks |
(Xia et al., 2009) |
CD31(+), VEGFR-2(+) |
Bone marrow |
Gene editing EPC therapy |
E2F1
deficiency EPCs improve the effect of EPC |
(S. Xu et al.,
2018) |
CD34(+), CD14(+), VEGFR-2(+) |
Peripheral blood |
Correlation between
EPC and PAH |
number of EPCs is negatively correlated with the PAH |
(P.
Liu et al., 2016) |
CD45(+), CD34(+), CD133(+) |
Peripheral blood |
Correlation between EPC
and PAH |
number of EPCs is significantly reduced in PAH patients |
(García-Lucio et al., 2017) |
CD34(+), AC133(+),
VEGFR-2(+)
|
Peripheral blood
|
Correlation between EPC and PAH
|
number of EPCs is significantly reduced in PAH patients
|
(Diller et al., 2008)
|
CD34(+), CD133(+) |
Peripheral blood |
Function of EPC therapy |
EPCs
can reduce the symptoms of PAH |
(Q. Zhao et al., 2007) |
CD31(+), VEGFR-2(+), vWF (+) |
Bone marrow |
Function of EPC therapy |
EPCs can alleviate PAH |
(C. K. Sun et al., 2012) |
CD34(+), CD133(+),
VEGFR-2(+)
|
Bone marrow
|
Function of EPC therapy
|
HIF1-EPCs can alleviate PAH
|
(Cao et al., 2015)
|
CD31(+), CD144(+), VEGFR-2(+) |
Peripheral blood |
Function of EPC
therapy |
EPCs can improve the function of RV |
(Loisel et al.,
2019) |
CD31(+), CD14(+), CD34(+), VEGFR-2(+) |
Peripheral blood |
Function of
EPC therapy |
EPCs show a no discernable therapeutic benefic |
(Ormiston, Deng, Stewart, & Courtman, 2010) |
CD31(+), VEGFR-2(+) |
Lung tissue |
Correlation between EPC and PAH |
number of EPCs is significantly reduced in PAH patients |
(Duong et al.,
2011) |
VEGFR-2(+), Tie2(+), CD14(+), CD31(+), CD34(+) |
Bone marrow |
Function
of EPC therapy |
Both COX1-PGIS-EPCs and EPCs can alleviate PAH |
(Zhou
et al., 2013) |
AC133(+), VEGFR-2(+) |
Peripheral blood |
Correlation between EPC and
PAH |
number of EPCs is significantly reduced in PAH patients |
(Junhui
et al., 2008) |
CD34(+), CD133(+),
VEGFR-2(+)
|
Peripheral blood
|
Correlation between EPC and lung disease
|
Progenitor cell types are present in the neointima of occluded
vessels
|
(Yao et al., 2009)
|
CD34(+), CD144(+), CD31(+), VEGFR-2(+), eNOS (+) |
Peripheral blood |
Function of EPC therapy |
Inhibition of ROCK reduced EPCs senescence and
alleviate PAH |
(B. Liu et al., 2016) |